Matthew Nettleman
Family Medicine · Lafayette, INNPI 1659756484
Payments from drug & device makers
Across 176 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$470
- AstraZeneca$331
- Lilly USA, LLC$260
- Pfizer$241
- Abbott$199
- Exact Sciences$179
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,850100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $470 |
| AstraZeneca | 15 | $331 |
| Lilly USA, LLC | 15 | $260 |
| Pfizer | 14 | $241 |
| Abbott | 10 | $199 |
| Exact Sciences | 9 | $179 |
| Boehringer Ingelheim | 10 | $151 |
| Amgen | 6 | $110 |
| GSK | 7 | $103 |
| Dexcom, Inc. | 6 | $100 |
| AbbVie(2 entities) | 4 | $78 |
| Johnson & Johnson | 4 | $70 |
| Medtronic(2 entities) | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $45 |
| Inspire Medical Systems, Inc. | 1 | $42 |
| Livanova USA, Inc. | 3 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Bayer | 1 | $37 |
| Novartis | 2 | $34 |
| Grifols USA, LLC | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Eisai Inc. | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Nalpropion Pharmaceuticals LLC | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Merck | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,858 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 184 | $201,964 |
| EliquisApixaban | 162 | $163,189 |
| JardianceEmpagliflozin | 101 | $106,555 |
| XareltoRivaroxaban | 46 | $56,797 |
| FarxigaDapagliflozin Propanediol | 53 | $49,328 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $37,569 |
| TrulicityDulaglutide | 28 | $36,051 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $29,879 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $29,633 |
| RybelsusSemaglutide | 19 | $25,349 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $22,951 |
| MyrbetriqMirabegron | 33 | $21,701 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $19,707 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $18,770 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $18,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $470 | $227,313203 claims |
| PfizerEliquis, Premarin | $241 | $168,833179 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Stiolto Respimat | $151 | $137,204141 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $331 | $78,985108 claims |
| GSKAnoro Ellipta, Breo Ellipta, Shingrix | $103 | $76,755194 claims |
| Johnson & JohnsonXarelto, Invokana | $70 | $75,14158 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $260 | $52,54944 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $21,70133 claims |
| MerckJanumet Xr | $12 | $16,32514 claims |
| NovartisEntresto | $34 | $15,80816 claims |
| AbbVieLinzess | $78 | $14,88822 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $13 | $13,77115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Lafayette
- William BrayLafayette$161K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.